

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/547,501
				Filing Date	April 12, 2000
				First Named Inventor	Christian, S.T.
				Group Art Unit	
				Examiner Name	
Sheet	1	of	11	Attorney Docket Number	IMI-002

RECEIVED

NJW 152000

~~TECH CENTER 1600/2900~~

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Duplicated copy


Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



+
RECEIVE
NOV 15 2000
TECH CENTER 1600/291

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 11

Complete if Known

Application Number	09/547,501
Filing Date	April 12, 2000
First Named Inventor	Christian, S.T.
Group Art Unit	
Examiner Name	
Attorney Docket Number	IMI-002

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Alexander, N., Yoneda, S., Vlachakis, N.D. and R.F. Maronde. 1984. Role of conjugation and red blood cells for inactivation of circulating catecholamines. Am. J. Physiol. 247 (1): R203-R207	
	2	Alvarado, F. and R.K. Crane. 1960. Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine, in vitro. Biochim. Biophys. Acta 56: 170-172.	
	3	Arita, H. and J. Kawanami. 1980. Studies on uptake of phenyl glycosides as inhibitors of D-glucose uptake by Rhesus monkey kidney cells. J. Biochem. 88: 1399-1406.	
	4	Barnett, J.E.G., Holman, G.D. and K.A. Munday. 1973. Structural requirements for binding to the sugar transport system of the human erythrocyte. Biochem. J. 131: 211-221.	
	5	Barnett, A., McQuade, R.D. and C. Tedford. 1992. Highlights of D1 dopamine receptor antagonist research. Neurochem. Int. 20 (Suppl.): 119S-122S.	
	6	Bencsics, A., Sershen, H., Baranyi, M., Hashim, A., Lajtha, A. and E.S. Vizi. 1997. Dopamine, as well as, norepinephrine, is a link between noradrenergic nerve terminals and splenocytes. Brain Res. 761 (2): 236-243.	
	7	Berger, J.G., Chang, W.K., Clader, J.W., Hou, D., Chipkin, R.E. and A.T. McPhail. 1989. Synthesis and receptor affinities of some conformationally restricted analogues of the dopamine D1 selective ligand (5R)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol. J. Med.	
	8	Brewster, W.K., Nichols, D.E., Riggs, R.M., Mottola, D.M., Lovenberg, T.W., Lewis, M.H. and R.B. Mailman. 1990. trans-10,11-dihydroxy-5,6,7,8,12b-hexahydrobenzo[a]phenanthridine: A highly potent selective dopamine D1 full agonist. J. Med. Chem. 33: 1756-1764.	
	9	Bodor, N., Roller, R.G. and S.J. Selk. 1978. Elimination of a quaternary pyridinium salt delivered as its dihydropyridine. J. Pharm. Sci. 67 (5): 685	
	10	Bodor, 1976. "Novel Approaches for the Design of Membrane Transport Properties of Drugs". In: "Design of Biopharmaceutical Properties Through Prodrugs and Analogs", Ed. E.B. Roche et al. APhA Academy of Pharmaceutical Sciences, Washington, D.C., pp. 98-135	
	11	Bodor, N., Farag, H.H. and M.E. Brewster. 1981. Site-specific, sustained release of drugs to the brain. Science 214: 1370-1372	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3 of 11

Complete if Known

Application Number	09/547,501
Filing Date	April 12, 2000
First Named Inventor	Christian, S.T.
Group Art Unit	
Examiner Name	
Attorney Docket Number	IMI-002

RECEIVED

NOV 15 2000

TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	12	Bodor, N. and J.W. Simpkins. 1983. Redox delivery systems for brain-specific, sustained release of dopamine. Science 221: 65-67.	
	13	Casagrande,C., Santagelo,F., Saini, C., Doggi, F., Gerli, F. and C. Cerri. 1986 Synthesis and chemical properties of Ibopamine and of related esters of N-substituted dopamines:Synthesis of Ibopamine metabolites. Arzneim.Forsch. 36 (2a): 291-303	
	14	Chen, N., Ferrer, J.V., Havitch, J.A. and J.B. Justice. 2000. Transport-dependent accessibility of a cytoplasmic loop cysteine in human dopamine transporter. J. Biol. Chem. 275 (3): 1608-1614.	
	15	Choi, S.W., Elmaleh, D.R., Hanson, R.N. and A.J. Fishman. 2000. Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: Synthesis and evaluation as dopamine transporter ligands. J. Med. Chem. 43 (2): 205-213.	
	16	Clarkson, E.D., Edwards-Prasad, J., Freed, C.R. and K.N. Prasad. 1999. Immortalized dopamine neurons: A model to study neurotoxicity and neuroprotection. Proc. Soc. Exp. Biol. Med. 222 (2): 157-163	
	17	Claustre, J., Pequignot, J.M., Bui-Xuan, B., Muchada, R., Cottet-Ermard, R.M. and L. Peyrin. 1990. Conjugation and deamination of circulating dopamine: Relationship between sulfated and free dopamine in man. J. Auton, Nerv. Syst. 29 (2): 175-182	
	18	Coffey, L.L. and M. Reith. 1994. [3H]WIN 35,428 binding to the dopamine uptake carrier. I. Effect of tonicity and buffer composition. J. Neurosci. Methods 51 (1): 23-30.	
	19	Dandridge, P.A., Kaiser, C., Brenner, M., Gaitanopoulos, D., Davis, L.D., Webb, R.L., Foley, J.J. and H.M. Sarau. 1984. J. Med. Chem. 27: 28	
	20	Diez-Sampedro, A., Urdaneta, E., Lostao, M.P. and A. Barber. 1999. Galactose transport inhibition by cytochalasin E in rat intestine in vitro. Can. J. Physiol. Pharmacol. 77 (2): 96-101	
	21	Duport, S., Robert, F., Muller, D., Grau, G., Parisi, L. and L. Stoppini. 1998. An in vitro blood-brain barrier model: Cocultures between endothelial cells and organotypic brain slice cultures. Proc. Natl. Acad. Sci. USA 95 (4): 1840-1845	
	22	Earles, C. and J.O. Shenk. 1999. Multisubstrate mechanism for the inward transport of dopamine by the human dopamine transporter expressed in HEK cells and its inhibition by cocaine. Synapse 33 (3): 230-238.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

11

Complete if Known

Application Number	09/547,501
Filing Date	April 12, 2000
First Named Inventor	Christian, S.T.
Group Art Unit	
Examiner Name	
Attorney Docket Number	IMI-002



RECEIVE

NOV 15 2000

PATENT & TRADEMARK OFFICE

TECH CENTER 1600/30

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	23	Figlewicz,D.P. 1999. Endocrine regulation of neurotransmitter transporters. Epilepsy Res. 37 (3): 203-210	
	24	Findlay, J., Levy, G.A. and C.A. Marsh. 1958. Inhibition of glycosidases by aldonolactones or corresponding configuration. 2. Inhibitors of b-N-acetylglucosaminidase. Biochemical J. 69: 467-476.	
	25	Fischer, Y., Thomas, Y., Kamp, J., Juengling, E., Rose, H., Carpen, C. and H. Kammermeier. 1995. 5-Hydroxytryptamine stimulates glucose transport in cardiomyocytes via a monoamine oxidase-dependent reaction. Biochem. J. 311 (2): 575-583.	
	26	Fodor et al. 1961. Acta Chim. Acad. Sci. Hung. 28 (4): 409.	
	27	Freeman, H.S. and J.D. McDermed. 1982. In: Chemical Regulation of Biological Mechanisms. Eds., Crieghton, A.M. and S. Turner. Royal Soc. Chemistry, London. pp 154-165	
	28	Gainetdinov, R.R., Jones, S.R. and M.G. Caron. 1999. Functional hyperdopaminergia in dopamine transporter knock-out mice. Biol. Psychiatry 46 (3): 303-311.	
	29	Gee, J.M., DuPont, M.S., Rhodes, M.J. and I.T. Johnson. 1998. Quercetin glucosides interact with the intestinal glucose transporter pathway. Free Radic. Biol. Med. 25 (1): 19-25	
	30	Gerding, T.K., Drenth, B.F.H., DeZeeuw, R.A., Tepper, P.G. and A.S. Horn. 1990. Metabolism and disposition of the dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetraline in conscious monkeys after subsequent iv, oral and ocular administration. Drug. Metab. Dispos. 18 (6): 923-928	
	31	Geurts,M., Hermans, E. and J.M. Maloteaux. 1999. Assessment of striatal D1 and D2 dopamine receptor-G protein coupling by agonist-induced [35S]GTP gamma S binding. Life Sci. 65 (16): 1633-1645.	
	32	Giros, B., el Mestikawy, S., Bertrand, L. and M.G. Caron. 1991. Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Lett. 295: 149-154.	
	33	Giros, B., el Mestikawy, S., Godinot, N., Zheng, K., Han, H., Yang-Feng, T. and M.G. Caron. 1992. Cloning, pharmacological characterization and chromosome assignment of the human dopamine transporter. Mol. Pharmacol. 42 (3): 383-390.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5 of 11

Complete if Known

Application Number	09/547,501
Filing Date	April 12, 2000
First Named Inventor	Christian, S.T.
Group Art Unit	
Examiner Name	
Attorney Docket Number	IMI-002



OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	34	Green, M.D. and T.R. Tephly. 1996. Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein. Drug Metab. Dispos. 24 (3): 356-363	
	35	Haspel, H.C., Stephenson, K.N., Davies-Hill, T., El-Barbary,A., Lobo, J.F., Croxen, R.L., Mougrabi, W., Koehler-Stec, E.M., Fenstermacher, J.D. and I.A. Simpson. 1999. Effects of barbiturates on facilitative glucose transporters are pharmacologically specific and isoform selective. J. Membr. Biol. 169 (1): 45-53	
	36	Hibert, M.F., Gittos, M.W., Middlemiss, D.N., Mir, A.K. and J.R. Fozard. 1988. Graphics computer-aided mapping as a predictive tool for drug design: Development of potent, selective and stereospecific ligands for the 5-HT1A receptor. J. Med. Chem. 31: 1087-1093	
	37	Horton, D. 1969. Monosaccharide Amino Sugars. In: "The Amino Sugars": The Chemistry and Biology of Compounds Containing Amino Sugars. Vol. 1A. Ed. R.W. Jeanloz. Academic Press, N.Y. pp. 4-18.	
	38	Hurtig, H.I. 1997. Problems with current treatment of Parkinson's disease. Exper. Neurol. 144: 10-16.	
	39	Husbands, S.M., Izenwasser, S., Kopajtic, T., Bowen, W.D., Vilner, B.J., Katz, J.L. and Newman, A.H. 1999. Structure-activity relationships at the monoamine transporters as sigma receptors for a novel series of 9-[3-(cis,5-dimethyl-1-piperazinyl)propyl] carbazole (rmicazole) analogues. J. Med. Chem. 42 (21): 4446-4455.	
	40	Hyson, D.H., Thomson, A.B. and C.T. Kappagoda. 1996. Calcium channel blockers modify jejunal uptake of D-galactose in rabbits. Dig. Dis. Sci. 41 (9): 1871-1875.	
	41	Hyson, D.H., Thomson, A.B., Keelan, M. and C.T. Kappagoda. 1997. A high cholesterol diet blocks the effect of calcium channel blockers on the uptake of sugars in rabbit intestine. Can. J. Physiol. Pharmacol. 75 (1): 57-64.	
	42	Iorio, L.C., Barnett, A., Billard, W. and E.H. Gold. 1986. Benzazepines structure-activity relationships between D1 receptor blockade and selected pharmacological effects. In: Neurobiology of Central D1 Dopamine Receptors, Eds., G.R. Breese and I. Creese, Plenum Press, NY. pp. 1-14.	
	43	Jaber, M., Dumartin, B., Sagne, C., Haycock, J.W., Roubert, C., Giros, B., Bloch, B. and M.G. Caron. 1999. Differential regulation of tyrosine hydroxylase in the basal ganglion of mice lacking the dopamine transporter. Eur. J. Neurosci. 11 (10): 3499-3511.	
	44	Jones, S.R., Joseph, J.D., Barak, L.S., Caron, M.G. and R.M. Wightman. 1999. Dopamine neuronal transport kinetics and effects of amphetamine. J. Neurochem. 73 (6): 2406-2414.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

6 of 11

Complete if Known

Application Number	09/547,501
Filing Date	April 12, 2000
First Named Inventor	Christian, S.T.
Group Art Unit	

RECEIVED

NOV 15 2000

Attorney Docket Number IMI-002

TECH CENTER 1600/2900

T²

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	45	Jork, R., Lossner, B. and H. Matthies. 1980. The influence of dopamine on the incorporation of different sugars into total proteins of hippocampal slices. Pharmacol. Biochem. Behav. 13 (2): 303-304.	
	46	Kaiser, C., Dandridge, P.A., Garvey, E., Hahn, R.A., Sarau, H.M., Setler, P.E., Bass, L.S. and J.Clardy. 1982. J. Med. Chem. 25: 697	
	47	Kawasaki, H. and M. Yago. 1983. The identification of two N-acetyldopamine glucosides in the left colletterial gland of the praying mantid, Tenodera aridifolia sinensis Saussure, and their role in the oothecal sclerotization .Insect Biochem. 13: 267-271	
	48	Kerwin, J.L. 1996. Negative ion electrospray mass spectrometry of polyphenols, catecholamines and their oxidation products. J. Mass Spectrom. 31: 1429-1439	
	49	Kerwin, J.L. 1997. Profiling peptide adducts of oxidized N-acetyldopamine by electrospray mass spectrometry. Rapid Commun. Mass Spectrom. 11: 557-566.	
	50	Kilbourn, M.R., Kuszpit, K. and P. Sherman. 2000. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Synapse 35 (4): 250-255.	
	51	Kilty, J.E., Lorang, D. and S.G. Amara. 1991. Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science 254 (5031): 578-579	
	52	Knoerzer, T.A., Nichols, D.E., Brewster, W.K., Watts, V.J., Mottola, D and R.B. Mailman. 1994. Dopaminergic benzo[a]phenanthridines: Resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist. J. Med. Chem. 37: 2453-2460.	
	53	Kuchel, O. 1999. Peripheral dopamine in hypertension and associated conditions. J. Hum. Hypertens. 13 (9): 605-615	
	54	Kuipers, W., Duse, C.G., van Wijngaarden, I., Standaar, P.J., Martin, T.M., Tulp, N.V., Spek, A.L. and A.P. Ijzerman. 1997. 5-HT1A vs. D2-receptor selectivity of Flesinoxan and analogous N4-substituted and N1-arylpiperazines. J. Med. Chem. 40: 300-312	
	55	Kumagai, A.K. 1999. Glucose transport in brain and retina: Implications in the management and complications of diabetes. Diabetes Metab. Res. Rev. 15 (4): 261-273.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

7 of 11

Complete if Known

Application Number	09/547,501
Filing Date	April 12, 2000
First Named Inventor	Christian, S.T.
Group Art Unit	
Examiner Name	
Attorney Docket Number	IMI-002

RECEIVED

NOV 15 2000

TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	56	Leal, M., Hayes, M.J. and M.L. Powell. 1992. The metabolism of CGS15873 in man using stable isotope pattern recognition techniques. Biopharm. Drug Dispos. 13 (8): 617-628.	
	57	Lichtenthaler, F.W. Efficient Reaction Channels from Mono- and Disaccharides to Enantiopure Building Blocks and Exploitation of Their Application Profiles. In: Carbohydrates: Synthetic Methods and Applications in Medicinal Chemistry, edited by Ogura, H., Hasegawa, A., and Suami, T. Tokyo:Kodansha, 1992,p. 3-27	
	58	Liljefors, T. and H. Wikstrom. 1986. A molecular mechanics approach to the understanding of presynaptic selectivity for centrally acting dopamine receptor agonists of the phenylpiperidine series. J. Med. Chem. 29: 1896.	
	59	van de Waterbeemd, V., Tayer, N.E., Testa, B., Wikstrom, H. and B. Largent. 1987. Quantitative structure-activity relationships and eudismic analyses of the presynaptic dopaminergic.... J. Med. Chem. 30: 2175	
	60	Lostao, M.P., Urdaneta, E., Martinez-Anso, E., Barber, A. and J.A. Martinez. 1998. Presence of leptin receptors in rat small intestine and leptin effect on sugar absorption. FEBS Lett. 423 (3): 302-306	
	61	Loland, C.J., Norregaard, L. and U. Gether. 1999. Defining proximity relationships in the tertiary structure of the dopamine transporter. Identification of a conserved glutamic acid third coordinate in the endogenous Zn ²⁺ binding site. J. Biol. Chem. 274: 36928-36934	
	62	Manzi, A.E. and A. Varki. 1993. In: Glycobiology: A Practical Approach. Eds. M. Fukuda and A. Kobata. IRL Press, Oxford University, Oxford. pp29-31	
	63	Martin, M.G., Turk, E., Lostao, M.P., Kerner, C. and E.M. Wright. 1996. Defects in Na ⁺ /glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption. Nat. Genet. 12 (2): 216-220.	
	64	Mattiuz, E., Franklin, R., Gillespie, T., Murphy, A., Bernstein, J., Chiur, A., Hotten, T. and K. Kassahun. 1997. Disposition and metabolism of olanzapine in mice, dogs and rhesus monkeys. Drug Metab. Dispos. 25 (5): 573-583	
	65	McDermed, J.D., Freeman, H.S. and R.M. Ferris. 1978. Enantioselective binding of (+) and (-) 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes and related agonists to dopamine receptors. In: Catecholamines: Basic and Clinical Frontiers, Eds., E. Usdin, I.J. Kopin and J. Barchas, Pergamon Press, NY. pp 568-570.	
	66	Meyer, W., Buehring, K.U., Steiner, K., Ungethüm, W. and E. Schnurr. 1992. Pharmacokinetics and first clinical experiences with an antihypertensive dopamine (DA2) agonist. Eur. Heart J. 13 (Suppl. D): 121-128.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

8 of 11

Complete if Known

Application Number	09/547,501
Filing Date	April 12, 2000
First Named Inventor	Christian, S.T.
Group Art Unit	
Examiner Name	
Attorney Docket Number	IMI-002

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	67	Mico, B.A., Swagzdis, J.E., Federowicz, D.A. and K. Straub. 1986. Function-group metabolism of dopamine-2 agonists: Conversion of 4-(2-di-N-propylaminoethyl)-2-(3H)-indolone to 4-(2-di-N-propylaminoethyl)-7-hydroxyl-2-(3H)-indolone. <i>J. Pharm. Sci.</i> 75 (10): 929-933	
	68	Melikian, H.E. and K.M. Buckley. 1999. Membrane trafficking regulates the activity of the human dopamine transporter. <i>J. Neurosci.</i> 19 (18): 7699-7710.	
	69	Miller, G.W., Gainetdinov, R.R., Levey, A.I. and M.G. Caron. 1999. Dopamine transporters and neuronal injury. <i>Trends Pharmacol. Sci.</i> 20(10): 424-429.	
	70	Minor, D.L., Wyrick, S.D., Charlson, P.S., Watts, V.J., Nichols, D.E. and R.B. Mailman. 1994. Synthesis and molecular modeling of 1-phenyl-1,2,3,4-tetrahydroisoquinolines and related 5,6,8,9-tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 dopamine antagonists. <i>J. Med. Chem.</i> 37: 4317-4328	
	71	Mizuma, T., Ohta, K. and S. Awazu. 1994. The beta-anomeric and glucose preferences of glucose transport carrier for intestinal active absorption of monosaccharide conjugates. <i>Biochim. Biophys. Acta</i> 1200 (2): 117-122	
	72	Mizuma, T., Ohta, K., Hayashi, M. and S. Awazu. 1992. Intestinal active absorption of sugar-conjugated compounds by glucose transport system: Implications for improvement of poorly absorbable drugs. <i>Biochem. Pharmacol.</i> 43: 2037-2039.	
	73	Mizuma, T., Ohta, K., Hayashi, M. and S. Awazu. 1993. Comparative study of active absorption by the intestine and disposition of anomers of sugar-conjugated compounds. <i>Biochem. Pharmacol.</i> 45 (7): 1520-1523.	
	74	Morgan, T.D., Hopkins, T.L., Kramer, K.J., Roseland, C.R., Czapala, T.H., Tomer, K.B. and Crow, F.W. 1987. N-b-Alanylnorepinephrine: Biosynthesis in insect cuticle and possible role in sclerotization. <i>Insect Biochem.</i> 17: 255-263.	
	75	Morgan, M.J. and K.B. Franklin. 1991. Dopamine receptor subtypes and formalin test analgesia. <i>Pharmacol. Biochem. Behav.</i> 40 (2): 317-322.	
	76	Mueller, D.D., Morgan, T.D., Wassenberg, J.D., Hopkins, T.L. and K.J. Kramer. 1993. ¹ H and ¹³ C NMR of 3-O and 4-O conjugates of dopamine and other catecholamines. <i>Bioconjug. Chem.</i> 4(1): 47-53.	
	77	Navarro, H., Arriuebo, M.P., Alcalde, A.I. and V. Sorribas. 1993. Effect of erythromycin on D-galactose absorption and sucrase activity in rabbit jejunum. <i>Can. J. Physiol. Pharmacol.</i> 71 (3-4): 191-194.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

9

of

11

Complete if Known

Application Number	09/547,501
Filing Date	April 12, 2000
First Named Inventor	Christian, S.T.
Group Art Unit	
Examiner Name	
Attorney Docket Number	IMI-002

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	78	Pettersson, I., Liljefors, T. and K. Bogeso. 1990. Conformational analysis and structure-activity relationships of selective dopamine D1 receptor agonists and antagonists of the benzazepine series. J. Med. Chem. 33: 2197-2204.	
	79	Pokorski, M. and Z. Matysiak. 1998. Fatty acid acylation of dopamine in the carotid body. Med. Hypothesis. 50 (2): 131-133.	
	80	Pocchiari, F., Pataccini, R., Castelnovo, P., Longo, A. and C. Casagrande. 1986. Ibopamine, an orally active dopamine-like drug: Metabolism and pharmacokinetics in rats. Arzneim. -Forsch. 36 (2A): 334-340.	
	81	Prakash, C., Cui, D., Baxter, J.G., Bright, G.M., Miceli, J. and K. Wilner. 1998. Metabolism and excretion of a new anxiolytic drug candidate, CP-93,393, in healthy male volunteers. Drug Metab. Dispos. 26 (5): 448-456	
	82	Prakash, K.R., Tamiz, A.P., Araldi, G.L., Zhang, M., Johnson, K.M. and A. Kozikowski. 1999. N-phenylalkyl-substituted tropane analogs of boat conformation of high selectivity for the dopamine versus serotonin transporter. Bioorg. Med. Chem. Lett. 9 (23): 3325-3328.	
	83	Ramaswamy, K., Bhattacharyya, B.R. and R.K. Crane. 1976. 1-O-acyl derivatives of glucose as non-penetrating inhibitors of glucose transport by hamster small intestine in vitro. Biochim. Biophys. Acta 443: 284-287.	
	84	Rhoads, D.B., Rosenbaum, D.H., Unsal, H., Isselbacher, K.J. and L.L. Levitsky. 1998. Circadian periodicity of intestinal Na ⁺ /glucose cotransporter 1 mRNA levels is transcriptionally regulated. J. Biol. Chem. 273 (16): 9510-9516.	
	85	Riggs, M.R., Nichols, D.E., Foreman, M.M., Truex, L.L., Glock, D. and J.D. Kohli. 1987. Specific dopamine D-1 and DA1 properties of 4-(mono- and dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline and its tetrahydrothieno [2,3-c] pyridine analogue. J. Med. Chem. 30: 1454-1458.	
	86	Schauer, R. 1978. In: Methods in Enzymology, Ed. V. Ginsberg. Academic Press, NY. pp. 64-89.	
	87	Seiler, M.P. and R. Markstein. 1982. Further characterization of structural requirements for agonists at the striatal dopamine D-1 receptor. Studies with a series of monohydroxyaminotetralins on dopamine-sensitive adenylate cyclase and comparison with dopamine receptor binding. Mol. Pharmacol. 22: 281-289.	
	88	Seiler, M.P. and R. Markstein. 1989. Characterization of dopamine receptor subtypes by comparative structure-activity relationships: dopaminomimetic activities....J. Mol. Pharmacol. 35: 643-651.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

10 of 11

Complete if Known

Application Number	09/547,501
Filing Date	April 12, 2000
First Named Inventor	Christian, S.T.
Group Art Unit	
Examiner Name	

Attorney Docket Number IMI-002



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	89	Seiler, M.P., Hagenbach, A., Wuthrich, H-J. and R. Markstein. 1991. trans-Hexahydroindolo[4,3-ab]phenanthridines ("Benzergolines"), the first structural class of potent and selective D1 receptor agonists lacking a catechol group. J. Med. Chem. 34 (1): 303-307.	
	90	Shimada, S., Kitayama, S., Lin, C.L., Patel, A., Nanthakumar, E., Gregor, P., Kuhar, M. and G. Uhl. 1991. Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science 254 (5031): 576-578.	
	91	Shindo, H., Komai, T. and K. Kawai. 1973. Metabolism of D- and L-isomers of 3,4 dihydroxyphenylalanine (DOPA). V. Mechanism of intestinal absorption of carbon-14 labeled D- and L-dopa in rats. Chem. Pharm. Bull 21 (9): 2031-2038	
	92	Shah, J.H., Kline, R.H., Geter-Douglass, B., Izenwasser, S., Witkin, J.M. and A.H. Newman. 1996. (+/-)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: Novel dopamine D1 receptor antagonists. J. Med. Chem. 39: 3423-3428.	
	93	Snyder, S.E., Aviles-Garay, F.A., Chakraborti, R., Nichols, D.E., Watts, V.J. and R.B. Mailman. 1995. Synthesis and evaluation of 6,7-dihydroxy-2,3,4,8,9,13b-hexahydro-1H-benzo[6,7]cycloheptal [1,2,3ef][3]benzazepine, 6,7-dihydroxy-2,3,4,8,9,12b-hexahydroanthra-[10,4a,4-c,d]azepine and 10-(aminomethyl)-9,10-dihydro-1,2-dihydroxyanthracene as conformationally restricted analogs of b-phenyldopamine. J. Med. Chem. 38: 2395-2409	
	94	Storch, A., Ludolph, A.C. and J. Schwarz. 1999. HEK-293 cells expressing the human dopamine transporter are susceptible to low concentrations of 1-methyl-4-phenylpuridine acting via impairment of energy metabolism. Neurochem. Int. 35 (5): 393-403	
	95	Sugamori, K.S., Lee, F.J., Pristupa, Z.B. and H.B. Niznik,. 1999. A cognate dopamine transporter-like activity endogenously expressed in a COS-7 kidney derived cell line. FEBS Lett. 451 (2): 169-174	
	96	Takata, K., H. Hirano and M. Kasahara. 1997. Transport of glucose across the blood-tissue barriers. Int. Rev. Cytology 172: 1-53.	
	97	Umegae, Y., H. Nohta and Y. Ohkura. 1988. Anal. Chim. Acta 208: 59.	
	98	Vandenbergh, D.J., Persico, A.M. and G.R. Uhl. 1992. A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs. Brain Res. Mol. Brain Res. 15 (1-2): 161-166.	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

11

of

11

Complete if Known

Application Number	09/547,501
Filing Date	April 12, 2000
First Named Inventor	Christian, S.T.
Group Art Unit	
Examiner Name	
Attorney Docket Number	IMI-002

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	99	Vannucci, S.J., Clark, R.R., Koehler-Stec, E., Li, K., Smith, C.B., Davies, P., Maher, F. and I.A. Simpson. 1998. Glucose transporter expression in brain: Relationship to cerebral glucose utilization. Dev. Neurosci. 20 (4-5): 369-379
	100	Verhoeff, N.P. 1999. Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders. Psychopharmacol. (Berl) 147 (3): 217-249
	101	Wang, P.C., Nguyen, T.B., Kuchel, O. and J. Genest. 1983. Conjugation patterns of endogenous plasma catecholamines in human and rat. J. Lab. Clin. Med. 101 (1): 141-151
	102	Wang, P.C., Kuchel, O., Buu, N.T. and J. Genest. 1983. Cathecholamine glucuronidation: An important metabolic pathway for dopamine in the rat. J. Neurochem. 40 (5): 1435-1440
	103	Weinstock, J., Hieble, J.P. and J.W. Wilson. 1985. Drugs Future 10: 645
	104	Whitfield, C.F., Rannels, S.R. and H.E. Morgan. 1974. Acceleration of sugar transport in avian erythrocytes by catecholamines. J. Biol. Chem. 249 (13): 4181-4188.
	105	Wright, E.M., Hirsch, J.R., Loo, D.D. and G.A. Zampighi. 1997. Regulation of Na ⁺ /glucose cotransporters. J. Exp. Biol. 200 (2): 287-293.
	106	Wu, X. and H.H. Gu. 1999. Molecular cloning of the mouse dopamine transporter and pharmacological comparison with the human homologue. Gene 233 (1): 163-170.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.